Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Dropped Today

By Joe Tenebruso – Jun 16, 2020 at 6:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is facing some formidable competition as it develops its coronavirus vaccine.

What happened

Shares of Moderna (MRNA -3.19%) fell 3.4% on Tuesday, as the race for a COVID-19 vaccine intensifies.

So what 

Several vaccine development projects that are employing similar technology as Moderna have recently received substantial funding. This includes projects led by German biotech CureVac -- which received a $337 million investment from the German government on Monday -- and Imperial College London, which received more than $50 million from the UK government. 

A person in a hazmat suit holding a liquid-filled tube.

Moderna stock fell on Tuesday. Will it the be first to develop a COVID-19 vaccine? Image source: Getty Images.

In all, more than 100 vaccines are currently being developed around the world. Moderna has some formidable rivals, including healthcare titans Johnson & Johnson, Pfizer, and AstraZeneca

Now what

Moderna CEO Stephane Bancel told Bloomberg that its efficacy data for its coronavirus vaccine candidate, mRNA-1273, could be available by Thanksgiving in a best-case scenario. Moderna is currently conducting a Phase 2 study of its experimental COVID-19 vaccine, and it plans to begin a Phase 3 study in July. 

With infection counts rising, governments across the world are scrambling to secure potential coronavirus vaccines and treatments. Moderna recently reached an agreement with Israel for the future purchase of its vaccine, should it prove both safe and effective. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$119.69 (-3.19%) $-3.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.